AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Encouraging early detection and breaking the silence around men’s health
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The company has received approval from DCGI to begin patient enrolment and dosing in the country
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Subscribe To Our Newsletter & Stay Updated